Skip to main content
. 2021 Mar 11;18(3):e1003534. doi: 10.1371/journal.pmed.1003534

Fig 2. Estimated cervical cancer cases averted.

Fig 2

Compared to status quo human papillomavirus (HPV) vaccination, cervical cancer cases averted were projected to continually increase as vaccination extended to women and men ages 30 years (blue), 35 years (orange), 40 years (grey), and 45 years (yellow). Results were calculated based on model projections over the lifetime of 10-year-old girls born in 1969–2009.